Home
    • Plans Blog Contact
    Monopar Therapeutics Inc logo

    Monopar Therapeutics Inc

    MNPR
    Last price US$110.12
    Market cap US$717.0m
    12M price change 135.20%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Halozyme Therapeutics IncHALO Industry peer Corcept Therapeutics IncorporatedCORT Industry peer Exelixis IncEXEL Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Monopar Therapeutics Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Espaol de Investigacin en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Monopar Therapeutics Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 14, 2026

    Quarterly result summary

    Net loss was -$3.9M. Cash was $137.5M.

    Net loss -$3.9M reported
    Cash $137.5M reported

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings material Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing FORM 8-K May 14, 2026 SEC filing FORM 10-Q May 14, 2026 SEC filing FORM 10-K/A Apr 01, 2026 SEC filing FORM 8-K Mar 27, 2026 SEC filing FORM 10-K Mar 27, 2026 Earnings release EXHIBIT 99.1 Mar 27, 2026 Earnings material EXHIBIT 99.1 Nov 13, 2025 SEC filing FORM 8-K Nov 13, 2025 SEC filing FORM 10-Q Nov 13, 2025 Earnings release EXHIBIT 99.1 Aug 12, 2025 SEC filing FORM 8-K Aug 12, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 0.00/5
    Monopar Therapeutics Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 1.20/5
    Monopar Therapeutics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Monopar Ther... MNPR US$717.0m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Monopar Therapeutics Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Monopar Ther... MNPR US$717.0m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 3.98/5
    Monopar Therapeutics Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Monopar Ther... MNPR US$717.0m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Monopar Therapeutics Inc logo

    Monopar Therapeutics Inc

    US$110.12

    US$717.0m

    -0.90%

    135.20%